Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR

Cross-species comparative studies have highlighted differences between human and mouse cystic fibrosis transmembrane conductance regulator (CFTR), the epithelial Cl− channel defective in cystic fibrosis (CF). Here, we compare the impact of the most common CF mutation F508del on the function of human and mouse CFTR heterologously expressed in mammalian cells and their response to CFTR modulators using the iodide efflux and patch-clamp techniques. Once delivered to the plasma membrane, human F508del-CFTR exhibited a severe gating defect characterized by infrequent channel openings and was thermally unstable, deactivating within minutes at 37°C. By contrast, the F508del mutation was without effect on the gating pattern of mouse CFTR, and channel activity demonstrated thermostability at 37°C. Strikingly, at all concentrations tested, the clinically approved CFTR potentiator ivacaftor was without effect on the mouse F508del-CFTR Cl− channel. Moreover, eight CFTR potentiators, including ivacaftor, failed to generate CFTR-mediated iodide efflux from CHO cells expressing mouse F508del-CFTR. However, they all produced CFTR-mediated iodide efflux with human F508del-CFTR-expressing CHO cells, while fifteen CFTR correctors rescued the plasma membrane expression of both human and mouse F508del-CFTR. Interestingly, the CFTR potentiator genistein enhanced CFTR-mediated iodide efflux from CHO cells expressing either human or mouse F508del-CFTR, whereas it only potentiated human F508del-CFTR Cl− channels in cell-free membrane patches, suggesting that its action on mouse F508del-CFTR is indirect. Thus, the F508del mutation has distinct effects on human and mouse CFTR Cl− channels.

[1]  D. Sheppard,et al.  Potentiation of the cystic fibrosis transmembrane conductance regulator Cl- channel by ivacaftor is temperature independent. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[2]  R. Young,et al.  Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del , 2018, Molecular Pharmacology.

[3]  T. Hwang,et al.  Structural mechanisms of CFTR function and dysfunction , 2018, The Journal of general physiology.

[4]  S. Rousseau,et al.  Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[5]  A. Ashare,et al.  Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[6]  S. Muallem,et al.  Original ResearchFull Report: Basic and Translational—PancreasRestoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice , 2017 .

[7]  M. Claustres,et al.  The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis. , 2017, The international journal of biochemistry & cell biology.

[8]  David Y. Thomas,et al.  Corrector combination therapies for F508del-CFTR. , 2017, Current opinion in pharmacology.

[9]  I. Braakman,et al.  Correcting CFTR folding defects by small‐molecule correctors to cure cystic fibrosis , 2017, Current opinion in pharmacology.

[10]  Y. Sohma,et al.  CFTR potentiators: from bench to bedside , 2017, Current opinion in pharmacology.

[11]  N. McCarty,et al.  Bacterial Sphingomyelinase is a State-Dependent Inhibitor of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) , 2017, Scientific Reports.

[12]  R. Ford,et al.  Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation* , 2017, The Journal of Biological Chemistry.

[13]  M. Gray,et al.  Role of CFTR in epithelial physiology , 2016, Cellular and Molecular Life Sciences.

[14]  H. Senderowitz,et al.  Potentiators exert distinct effects on human, murine, and Xenopus CFTR. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[15]  D. Meyerholz,et al.  Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility. , 2016, American journal of respiratory and critical care medicine.

[16]  David K. Meyerholz,et al.  Airway acidification initiates host defense abnormalities in cystic fibrosis mice , 2016, Science.

[17]  N. McCarty,et al.  Murine and human CFTR exhibit different sensitivities to CFTR potentiators. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[18]  D. Sheppard,et al.  Exploiting species differences to understand the CFTR Cl- channel. , 2015, Biochemical Society transactions.

[19]  Asmahan Abu-Arish,et al.  Cholesterol modulates CFTR confinement in the plasma membrane of primary epithelial cells. , 2015, Biophysical journal.

[20]  I. Callebaut,et al.  Impact of the F508del mutation on ovine CFTR, a Cl− channel with enhanced conductance and ATP‐dependent gating , 2015, The Journal of physiology.

[21]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[22]  A. Toye,et al.  CFTR potentiators partially restore channel function to A561E‐CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del‐CFTR , 2014, British Journal of Pharmacology.

[23]  O. Moran,et al.  Direct interaction of a CFTR potentiator and a CFTR corrector with phospholipid bilayers , 2014, European Biophysics Journal.

[24]  N. Pedemonte,et al.  Structure and function of TMEM16 proteins (anoctamins). , 2014, Physiological reviews.

[25]  Marisa Sousa,et al.  Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. , 2013, Chemistry & biology.

[26]  G. Lukács,et al.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.

[27]  T. Hwang,et al.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle , 2013, Proceedings of the National Academy of Sciences.

[28]  C. Bear,et al.  Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner* ♦ , 2012, The Journal of Biological Chemistry.

[29]  Pradeep Kota,et al.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. , 2012, Journal of molecular biology.

[30]  G. Lukács,et al.  Comparative Processing and Function of Human and Ferret Cystic Fibrosis Transmembrane Conductance Regulator* , 2012, The Journal of Biological Chemistry.

[31]  K. Du,et al.  Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.

[32]  Philip J. Thomas,et al.  Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.

[33]  M. Welsh,et al.  Human–mouse cystic fibrosis transmembrane conductance regulator (CFTR) chimeras identify regions that partially rescue CFTR-ΔF508 processing and alter its gating defect , 2011, Proceedings of the National Academy of Sciences.

[34]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[35]  K. Kirk,et al.  Thermally Unstable Gating of the Most Common Cystic Fibrosis Mutant Channel (ΔF508) , 2011, The Journal of Biological Chemistry.

[36]  T. Hwang,et al.  The most common cystic fibrosis‐associated mutation destabilizes the dimeric state of the nucleotide‐binding domains of CFTR , 2011, The Journal of physiology.

[37]  L. Touqui,et al.  Mouse models of cystic fibrosis: phenotypic analysis and research applications. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[38]  Tzyh-Chang Hwang,et al.  On the mechanism of CFTR inhibition by a thiazolidinone derivative , 2010, The Journal of general physiology.

[39]  Philip J. Thomas,et al.  The Primary Folding Defect and Rescue of ΔF508 CFTR Emerge during Translation of the Mutant Domain , 2010, PloS one.

[40]  J. Clancy,et al.  DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. , 2010, Pulmonary pharmacology & therapeutics.

[41]  Bart Kus,et al.  Correction of the ΔPhe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine , 2010, Molecular Pharmacology.

[42]  N. Pedemonte,et al.  Influence of cell background on pharmacological rescue of mutant CFTR. , 2010, American journal of physiology. Cell physiology.

[43]  D. Sheppard,et al.  Direct Sensing of Intracellular pH by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl− Channel*♦ , 2009, The Journal of Biological Chemistry.

[44]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[45]  Gui Jun Yu,et al.  4'-Methyl-4,5'-bithiazole-based correctors of defective delta F508-CFTR cellular processing. , 2008, Bioorganic & medicinal chemistry letters.

[46]  M. Amaral,et al.  Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator , 2008, British journal of pharmacology.

[47]  Donglei Zhang,et al.  Structural Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect , 2008, Molecular Pharmacology.

[48]  D. Porteous,et al.  Chimeric constructs endow the human CFTR Cl− channel with the gating behavior of murine CFTR , 2007, Proceedings of the National Academy of Sciences.

[49]  M. Welsh,et al.  Processing and function of CFTR-ΔF508 are species-dependent , 2007, Proceedings of the National Academy of Sciences.

[50]  A. Houtsmuller,et al.  Cholesterol Depletion and Genistein as Tools to Promote F508delCFTR Retention at the Plasma Membrane , 2007, Cellular Physiology and Biochemistry.

[51]  Zhe Lu,et al.  Inhibition of CFTR Cl− channel function caused by enzymatic hydrolysis of sphingomyelin , 2007, Proceedings of the National Academy of Sciences.

[52]  S. Al’Aref,et al.  2,3-Butanedione Monoxime Affects Cystic Fibrosis Transmembrane Conductance Regulator Channel Function through Phosphorylation-Dependent and Phosphorylation-Independent Mechanisms: The Role of Bilayer Material Properties , 2006, Molecular Pharmacology.

[53]  T. Kirchhausen,et al.  Dynasore, a cell-permeable inhibitor of dynamin. , 2006, Developmental cell.

[54]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[55]  A. Taddei,et al.  Differential Sensitivity of the Cystic Fibrosis (CF)-associated Mutants G551D and G1349D to Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl– Channel* , 2006, Journal of Biological Chemistry.

[56]  Kai Du,et al.  Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. , 2005, The Journal of clinical investigation.

[57]  J. Clancy,et al.  Activating Cystic Fibrosis Transmembrane Conductance Regulator Channels with Pore Blocker Analogs* , 2005, Journal of Biological Chemistry.

[58]  Nicoletta Pedemonte,et al.  Phenylglycine and Sulfonamide Correctors of Defective ΔF508 and G551D Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating , 2005, Molecular Pharmacology.

[59]  Paola Vergani,et al.  CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains , 2005, Nature.

[60]  D. Sheppard,et al.  Voltage-dependent Gating of the Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channel , 2003, The Journal of general physiology.

[61]  T. Ma,et al.  Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating* , 2003, Journal of Biological Chemistry.

[62]  Chao Quan,et al.  Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. , 2003, Bioorganic & medicinal chemistry.

[63]  Nancy F. Hansen,et al.  Comparative analyses of multi-species sequences from targeted genomic regions , 2003, Nature.

[64]  R. Sammelson,et al.  3-(2-Benzyloxyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. , 2003, Bioorganic & medicinal chemistry letters.

[65]  R. Sammelson,et al.  CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[66]  W. Tanner,et al.  Specific lipid requirements of membrane proteins--a putative bottleneck in heterologous expression. , 2003, Biochimica et biophysica acta.

[67]  A. Nairn,et al.  On the Mechanism of MgATP-dependent Gating of CFTR Cl− Channels , 2003, The Journal of general physiology.

[68]  L. Gansheroff,et al.  Mutations in the Nucleotide Binding Domain 1 Signature Motif Region Rescue Processing and Functional Defects of Cystic Fibrosis Transmembrane Conductance Regulator ΔF508* , 2002, The Journal of Biological Chemistry.

[69]  M. Amaral,et al.  The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. , 2002, The Biochemical journal.

[70]  D. Sheppard,et al.  Molecular pharmacology of the CFTR Cl- channel. , 1999, Trends in pharmacological sciences.

[71]  J. Riordan,et al.  Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. , 1999, Molecular cell.

[72]  R. Frizzell,et al.  Rescue of Dysfunctional ΔF508-CFTR Chloride Channel Activity by IBMX , 1999, The Journal of Membrane Biology.

[73]  B. Wainwright,et al.  Regulation of murine cystic fibrosis transmembrane conductance regulator Cl− channels expressed in Chinese hamster ovary cells , 1998, The Journal of physiology.

[74]  D. Sheppard,et al.  Comparison of the gating behaviour of human and murine cystic fibrosis transmembrane conductance regulator Cl− channels expressed in mammalian cells , 1998, The Journal of physiology.

[75]  D. Sheppard,et al.  Mechanism of Glibenclamide Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channels Expressed in a Murine Cell Line , 1997, The Journal of physiology.

[76]  P. French,et al.  A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. , 1996, The Journal of clinical investigation.

[77]  M. Donowitz,et al.  Genistein and tyrphostin 47 stimulate CFTR-mediated Cl- secretion in T84 cell monolayers. , 1995, The American journal of physiology.

[78]  K. Thomas,et al.  A mouse model for the delta F508 allele of cystic fibrosis. , 1995, The Journal of clinical investigation.

[79]  H. Morreau,et al.  A mouse model for the cystic fibrosis delta F508 mutation. , 1995, The EMBO journal.

[80]  B. Abella,et al.  Generation and characterization of a ΔF508 cystic fibrosis mouse model , 1995, Nature Genetics.

[81]  R. Frizzell,et al.  ATP alters current fluctuations of cystic fibrosis transmembrane conductance regulator: evidence for a three-state activation mechanism , 1994, The Journal of general physiology.

[82]  V. Gribkoff,et al.  The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. , 1994, The Journal of biological chemistry.

[83]  C. Cotton,et al.  Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[84]  S Grinstein,et al.  The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. , 1993, The Journal of biological chemistry.

[85]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[86]  P. Parker,et al.  Dual role for protein kinase C alpha as a regulator of ion secretion in the HT29cl.19A human colonic cell line. , 1992, The Biochemical journal.

[87]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[88]  H. A. Berger,et al.  Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. , 1991, The Journal of clinical investigation.

[89]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[90]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[91]  Kaye Walizer Defective , 2021, Encyclopedia of the UN Sustainable Development Goals.

[92]  C. Goss,et al.  Cystic fibrosis , 2015, Nature Reviews Disease Primers.

[93]  J. Forrest,et al.  Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. , 2012, American journal of physiology. Cell physiology.

[94]  John R Yates,et al.  Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.

[95]  M. Welsh,et al.  Processing and function of CFTR-DeltaF508 are species-dependent. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Karl Kuchler,et al.  ABC proteins : from bacteria to man , 2003 .

[97]  L. Gansheroff,et al.  Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. , 2002, The Journal of biological chemistry.

[98]  R. Frizzell,et al.  Rescue of dysfunctional deltaF508-CFTR chloride channel activity by IBMX. , 1999, The Journal of membrane biology.

[99]  R. Crystal,et al.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. , 1991, Nature.

[100]  REVIEW Ion Channels and Transporters in Lung Function and Disease Ion channels of the lung and their role in disease pathogenesis , 2022 .